EFESA AA-Med Pty Ltd
Product name
EFESA
Sponsor
Accepted date
Nov-2024
Active ingredients
efepoetin alfa
Proposed indication
EFESA is indicated for the treatment of anaemia (reduced red cells/haemoglobin) in non-dialysis chronic kidney disease.
Application type
A (new medicine)
Publication date
Nov-2024